http://www.nlm.nih.gov/databases/alerts/foscarnet.html
Important information on survival in_persons with AIDS who have CMV retinitis is being_provided as a Clinical Alert (summary follows),
multicenter clinical trial designed to evaluate the relative efficacy and safety of foscarnet and ganciclovir for the initial treatment of CMV retinitis.
Foscarnet and ganciclovir appeared to be equally effective in halting the progression of CMV retinitis and preserving vision.
in the group of patients who entered the study with a predicted creatinine clearance These findings suggest that foscarnet may_be the preferable initial treatment for CMV retinitis, with the exception
The trial was_designed to evaluate the relative efficacy and safety of foscarnet and ganciclovir for the initial treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
or to other chance factors. Foscarnet and ganciclovir appeared to be equally effective in halting the progression of CMV retinitis
such an explanation cannot be_ruled out. These findings suggest that foscarnet may_be the preferable initial treatment for CMV retinitis. A possible exception is the subgroup of patients with decreased renal function (predicted creatinine
clearance The complete findings from this study will_be_published soon. This announcement is being_sent in_advance_of journal publication to physicians likely to treat patients with AIDS who have CMV retinitis. A press_conference was_held on October